| Filed On | Filing |
|---|---|
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
– Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 – |
| 29 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
Mineralys Therapeutics, Inc. (the Company) and Tanabe Pharma Corporation (Tanabe) were previously parties to that certain License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023, May 29, 2025 and June 2, 202... |
| 20 Oct 2026 |
Form 4: Peterson Kristine, Director
Received 12,400 shares as a grant or award · Granted 16,600 Stock Option |
| 20 Oct 2026 |
Form 3: Peterson Kristine, Director
No securities owned |
| 20 Oct 2026 |
Form 4: Coats Lonnel, Director
Received 12,400 shares as a grant or award · Granted 16,600 Stock Option |
| 20 Oct 2026 |
Form 3: Coats Lonnel, Director
No securities owned |
| 19 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 16, 2026, the Board of Directors (the Board) of Mineralys Therapeutics, Inc. (the Company) appointed Kristine Peterson and Lonnel Coats to the Board effective as of October 19, 2026, increasing the size of the Board from seven... |
| 13 Oct 2026 | 144 |
| 02 Oct 2026 |
Form 4: Congleton Jon, Director
Sold 75,000 shares ($1.91M) |
| 30 Sep 2026 | 144 |
| 24 Sep 2026 |
Form 4: Slingsby Brian Taylor, Director
Sold 104,320 shares ($3.01M) |
| 22 Sep 2026 |
Form 4: Warren Eric, Chief Commercial Officer
Received 7,438 shares by exercise or conversion ($98.5K) · Sold 7,438 shares ($209K) |
| 22 Sep 2026 | 144 |
| 21 Sep 2026 | 144 |
| 17 Sep 2026 |
Form 4: Karydas Daphne, Director
Received 3,000 shares by exercise or conversion ($36.1K) · Sold 3,000 shares ($85.7K) |
| 17 Sep 2026 | 144 |
| 15 Sep 2026 | 144 |
| 14 Sep 2026 | 144 |
| 09 Sep 2026 | 144 |
Loading...